Aberdeen Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Aberdeen Wealth Management's BMY Position: Q3 2026 in Review
Aberdeen Wealth Management reduced its Bristol-Myers Squibb (BMY) stake by 5.6% in Q3 2026, selling an estimated $19K and leaving 5,029 shares worth $314K. The position accounts for 0.12% of the portfolio, ranked #121.
Aberdeen Wealth Management first reported a position in BMY in Q4 2019 and has held it in 28 quarters since. The position peaked at $577K in Q2 2022. 2,533 funds tracked by Wall St. Rank hold BMY as of Q3 2026.
- Aberdeen Wealth Management held 5,029 shares of Bristol-Myers Squibb worth $314K as of Q3 2026.
- Aberdeen Wealth Management sold 300 Bristol-Myers Squibb shares in Q3 2026, an estimated $19K.
- Bristol-Myers Squibb made up 0.12% of Aberdeen Wealth Management's portfolio in Q3 2026, its #121 holding.
- Aberdeen Wealth Management first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 28 quarters since.
- Aberdeen Wealth Management's Bristol-Myers Squibb position peaked at $577K in Q2 2022.
- 2,533 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.
Based on Aberdeen Wealth Management's 13F filing for Q3 2026, filed 16 Nov 2026.